The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Granulomatosis of Wegener’s

The Granulomatosis of Wegener’s

May 16, 2011 • By Wolfgang L. Gross, MD, PhD, Antje Mueller, PhD, and Julia Holle, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
The Granulomatosis of Wegener's

Editor’s Note: The nomenclature for Wegener’s recently changed from Wegener’s granulomatosis to granulomatosis with polyangiitis (Wegener’s). Beginning with the June 2011 publication of The Rheumatologist, the new nomenclature will be used. See “Medical Societies Ask, What’s in a Name?“ on p. 48 for more on the evolution of disease nomenclature.

You Might Also Like
  • Granulomatosis with Polyangiitis: A Case Review
  • Wegener’s Granulomatosis Treatment Today
  • The Classification & Diagnosis of Granulomatosis with Polyangiitis
Explore This Issue
May 2011

Wegener’s granulomatosis (WG) is per definitionem a granulomatous disorder involving the respiratory tract and is usually associated with vasculitis, affecting small to medium-sized vessels and the production of antibodies to neutrophil cytoplasmic antigens (ANCA) directed to the antigen proteinase 3 (PR3).1 Although vasculitis may be its classical feature, WG also may occur as a persistent granulomatous inflammatory process without apparent vasculitis.2 While there is no clear definition of granulomatous disease in WG, this pathological process relates to the formation of masses (often round in appearance on radiograph) or the histological picture of granuloma that is frequently detected within these masses. We know about the vasculitic side of WG’s coin; much less is known about the granulomatous side of WG, however. In this article, we will focus on recent clinical and immunopathological findings attributed to the so-far enigmatic granulomatous process and the probable link to the development of PR3-ANCA and vasculitis.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Categorizing Disease Stages

WG is commonly considered to be part of the spectrum of disorders characterized by vasculitic lesions throughout the body without a known cause but associated with autoantibodies against PR3-ANCA.4 Therefore, WG is included into the group of diseases known as primary systemic vasculitides and grouped together with others (e.g., microscopic polyangiitis, Churg-Strauss syndrome) also strongly associated with ANCA and “pauci-immune” glomerulonephritis in situ.2 There is strong evidence for the pathogenic role of antibodies against myeloperoxidase (MPO-ANCA) in inducing vasculitis, and this mechanism may also play a role in PR3-ANCA associated vasculitis such as WG.5 However, the clinical and pathological hallmark of WG is not only vasculitis but the coexistence of vasculitis and granuloma, both of which differentiate WG from microscopic polyangiitis. The presence of two distinct pathological processes needs to be considered in categorizing disease stages in WG.

Figure 1: Destructive lesions in WG.
Credit: Left and middle panels, New Engl J Med. 2005;352:392;
right panel, Arthritis Rheum. 2008;58:834.
Reprinted with permission.
Figure 1: Destructive lesions in WG. Left panel: Necrotizing inflammation of the right lower eyelid and collapse of the nasal bridge. Middle panel: Computed tomographic scan displaying a retro-orbital mass and destruction of the orbital wall. Right Panel: Histopathology revealed granulomatous and ulcerative inflammation with active destruction of nasal septal cartilage.36,37

Currently, there are two approaches to categorize disease stages in ANCA-associated vasculitis (AAV). In the United States, it is common to differentiate a limited form of WG in which patients suffer from non–life-threatening vasculitis manifestations from a severe form with life-threatening vasculitic manifestations, such as glomerulonephritis.6 In contrast, the European approach separates a disease stage with granulomatous manifestations of the upper and lower respiratory tract (and with no clinical signs of vasculitis) from systemic disease stages with granulomatous and vasculitic manifestations (early systemic, non–life-threatening; generalized, organ-threatening; and severe with organ failure).7,8

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: Diagnostic Criteria, granulomatosis with polyangiitis, Pathogenesis, Treatment, Wegener's GranulomatosisIssue: May 2011

You Might Also Like:
  • Granulomatosis with Polyangiitis: A Case Review
  • Wegener’s Granulomatosis Treatment Today
  • The Classification & Diagnosis of Granulomatosis with Polyangiitis
  • Case Illustrates the Difficulty Diagnosing Granulomatosis with Polyangiitis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)